in 25 patients with primary dyslipoproteinemias and severe premature atherosclerosis , during an average combined lopid-mevacor treatment span of 12.5 months per patient , our specific aim was to assess safety and efficacy of open-label therapy with diet , gemfibrozil ( lopid ) , and lovastatin ( mevacor ) .
C0017245
gemfibrozil
C0700003
lopid